HER-2-Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents

Annals of the New York Academy of Sciences

Volumn 1002, Issue , 2003, Pages 78-89

  Rait, Antonina S ^a   Pirollo, Kathleen F ^a   Ulick, David ^a   Cullen, Kevin ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotides; Apoptosis; Chemosensitization; Head and neck cancer cell lines; HER 2; Ligand liposome delivery

Indexed keywords

ANTIINFECTIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLIC ACID; LIPOSOME; RHODAMINE;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; COMPLEX FORMATION; CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; GENE TARGETING; HEAD CANCER; HUMAN; HUMAN CELL; ISOTOPE LABELING; NECK CANCER; ONCOGENE NEU; PROTEIN EXPRESSION; START CODON; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

EID: 1342311410     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1281.018     Document Type: Conference Paper

References (45)

1. DOUGALL, W.C. et al. 1994. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109-2123.
2. TZAHAR, E. & Y. YARDEN. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1377: M25-M37.
3. O-CHAROENRAT, P., P.H. RHYS-EVANS, H. MODJTAHEDI & S.A. ECCLES. 2002. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol. 38: 627-640.
4. KING, C.R., M.H. KRAUS & S.A. AARONSON. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976.
5. KING, C.R. et al. 1989. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res. 49: 4185-4191.
6. SLAMON, D.J. et al. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
7. SLAMON, D.J. et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
8. KRAUS, M.H., N.C. POPESCU, S.C. AMSBAUGH & C.R. KING. 1987. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6: 605-610.
9. BERGER, M.S. et al. 1985. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48: 1238-1243.
10. TAL, M. et al. 1988. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res. 48: 1517-1520.
11. SKALOVA, A. et al. 2001. Salivary duct carcinoma - a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol. Res. Pract. 197: 621-626.
12. Yu, D. et al. 1996. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365.
13. LANGTON-WEBSTER, B.C., J.A. XUAN, J.R. BRINK & D.S. SALOMON. 1994. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ. 5: 1367-1372.
14. ARTEAGA, C.L. et al. 1994. p185c-3rbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 54: 3758-3765.
15. BECKHARDT, R.N. et al. 1995. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 121: 1265-1270.
16. WALCH, A.K. et al. 2000. Molecular genetic changes in metastatic primary Barrett's adnocarcinoma and related lymph node metastases: comparsion with nonmetastatic Barrett's adenocarcinoma. Mod. Pathol. 7: 814-824.
17. TANNAPFEL, A. & A. WEBER. 2001. Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur. Arch. Oto-rhinolaryngol. 2: 83-88.
18. AZEMAR, M. et al. 2000. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int. J. Cancer 2: 269-275.
19. WERKMEISTER, R., B. BRANDT & U. JOOS. 2000. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol. 36: 100-105.
20. IBRAHIM, S.O. et al. 1999. Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigens) in oropharyngeal squamous cell carcinomas. Oral Oncol. 35: 302-313.
21. XIA, W. et al. 1999. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin. Cancer Res. 84: 188-191.
22. O-CHAROENRAT, P., P.H. RHYS-EVANS & S.A. ECCLES. 2000. Expression and regulation of c-erbB ligands in human head and neck squamous carcinoma cells. Int. J. Cancer 88: 759-765.
23. BASELGA, J. & L.A. HAMMOND. 2002. HER-targeted tyrosine-kinase inhibitors. Oncology 63(Suppl. 1): 6-16.
24. WERKMEISTER, R. et al. 1999. Chemosensitivity testing of oral cancer cells treated with p185neu-specific agent. Eur. J. Oral Sci. 5: 338-343.
25. LORUSSO, P.M. 2003. Phase I studies of ZD1839 in patients with common solid tumors. [Review] [49 refs]. Semin. Oncol. 30: 21-29.
26. SARTOR, C.I. 2003. Epidermal growth factor family receptors and inhibitors: radiation response modulators. [Review] [55 refs]. Semin. Radiat. Oncol. 13: 22-30.
27. PIROLLO, K.F. et al. 1997. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem. Biophys. Res. Commun. 230: 196-201.
28. RAIT, A., J.E. KRYGIER, K. PIROLLO & E.H. CHANG. 1999. Sensitization of Breast Cancer Cells to Taxol by Antisense HER-2 Oligonucleotides. Antisense Nucleic Acid Drug Dev. 9: 403-408.
29. RAIT, A.S. et al. 2001. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther. 8: 728-739.
30. RAIT, A.S. et al. 2002. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irresective of HER-2 levels. Mol. Med. 8: 475-486.
31. TEICHER, B.A. et al. 1987. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 47: 388-393.
32. XU, L. et al. 1999. Systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Targeting 4: 92-104.
33. SCUDIERO, D.A. et al. 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48: 4827-4833.
34. KOOPMAN, G. et al. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420.
35. O-CHAROENRAT, P., P. RHYS-EVANS & S.A. ECCLES. 2001. Characterization of ten newly-derived human and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res. 21: 1953-1963.
36. KAZKAYASI, M., S. HUCUMENOGLU, G.I. SIRINER & M. HUCUMENOGLU. 2001. Overexpression of p53 and c-erbB-2 oncoproteins in laryngeal carcinoma. Eur. Arch. OtoRhino-Laryngol. 258: 329-335.
37. WERKMEISTER, R., B. BRANDT & U. JOOS. 1996. The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. Am. J. Surg. 172: 681-683.
38. IBRAHIM, S.O. et al. 1997. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res. 17: 4529-4546.
39. HOU, L. et al. 1992. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett. 65: 215-220.
40. SHIGA, H. et al. 2000. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head & Neck 22: 599-608.
41. KHADEMI, B. et al. 2002. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett. 184: 223-230.
42. NEWKIRK, K. et al. 1997. Glutathione, content but gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cell lines. Cancer Chemother. Pharmacol. 40: 75-80.
43. SCHRIJVERS, D. & J.B. VERMORKEN. 1998. Update on the taxoids and other new agents in head and neck cancer therapy. Curr. Opin. Oncol. 10: 233-241.
44. KOJIMA, H. et al. 1998. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem. 273: 16647-16650.
45. PIROLLO, K.F., A. RAIT, L.S. SLEER & E.H. CHANG. 2003. Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther. 99: 55-77.